Patent · US Active

PCSK9 iRNA compositions and methods of use thereof

US10125369B2 · kind B2 · utility

4Cited by

129References

85Claims

0Family size

Assignee

Alnylam Pharmaceuticals, Inc. · US

Inventors

Anna Borodovsky · Cambridge, US
Kallanthottathil G. Rajeev · Wayland, US
Kevin Fitzgerald · Brookline, US
Maria Frank-Kamenetsky · Brookline, US
William Querbes · Boston, US
Martin Maier · Cambridge, US
Klaus Charisse · Acton, US
Satyanarayana Kuchimanchi · Cambridge, US
Muthiah Manoharan · Carlsbad, US
Stuart Milstein · Cambridge, US

Key dates

Filing date	Dec 5, 2013
Grant date	Nov 13, 2018
Priority date	—
Expiry date	Jun 26, 2034

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2320/35
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention relates to RNAi agents, e.g., double-stranded RNAi agents, targeting the PCSK9 gene, and methods of using such RNAi agents to inhibit expression of PCSK9 and methods of treating subjects having a lipid disorder, such as a hyperlipidemia.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.